Clinical application | Biomarkers | Status |
---|---|---|
Investigation of pelvic mass | • CA 125 and HE4 (+ ROMA)a • CA 125 and 7 proteomic markers (+ Danish-Index)b | • FDA-approved (2011) • FDA-approved (2009) |
Improve PSA specificity in screening | • Serum PSA and urine PCA-3 and TMPRSS2-ERG fusionsc | • Pending FDA approval |
Separate indolent from aggressive prostate cancer | • PTEN lossc • TMPRSS2-ERG fusions3 | • More research necessarye |
Assess risk of malignancy of thyroid nodules with indeterminate results on biopsy | • HBME-1, Galectin-3 and CK19d | • More research necessary |
Assess risk of malignancy of CT (± PET) imaging-identified indeterminate lung masses | • CEA, CYFRA 21-1, SCC, CA15.3, Pro-GRP, NSE | • More research necessary |